<DOC>
	<DOCNO>NCT02168426</DOCNO>
	<brief_summary>The purpose study evaluate efficacy Seprafilm guardix reduce incidence bowel obstruction evaluate incidence serious adverse event ( SAEs ) associate use Seprafilm guardix occur within 30 day postoperatively .</brief_summary>
	<brief_title>Randomized Control Trial Seprafilm Guardix Preventing Ileus</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Clinical diagnosis GI cancer Operable Withdrew consent Pregnant Ascites Distant metastasis Liver dysfunction ( serum total bilirubin &gt; 2.0 mg/dL ) Renal failure ( serum creatinine &gt; 1.5 mg/dL ) A past history small bowel obstruction .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>